Aug. 20 at 11:09 PM
$PDSB if you’re not buying at this price, then you’ve got no clue about biotech investing. No matter how bad it looks, there’s data to show this company has something of value that could eventually be unlocked at some point. Forget about Frank, he’s a Turd. But the NCI is trialing PDSB0301 in MSS CRC with, and I repeat, with LIVER metastasis!! That’s about as difficult as it gets with CRC… and the early data is 71% ORR and 2-yr survival of over 80%… Yes, N=9 is small, and it isn’t a randomized trial but the difficulty level of the patient setting - I.e Metastatic MMS CRC cancer speaks huge volume about potentials… and as a biotech investor, that’s all you can ask for. At this price level, I will be gobbling and gobbling. Even if are Wes split happens, so be it. So many Oncology plays have been bought after multiple rounds of reverse split in
$BILLIONS deals. Be scared when others are giddy and be giddy when others are fearful !! That’s the easiest rule in the market !
